In contrast, GPC3-CAR T cells were less cytotoxicity to tumors in PDX3 that were more aggressive and highly expressed PD-L1, suggesting that we need to combine CAR T cell therapy and immune checkpoint inhibitors to achieve higher efficacy of eliminating PD-L1-positive HCC. Here, GPC3 is linked to hepatocellular carcinoma.